MedTrace Logo

Evaluation of Efficacy and Safety of Prolia in Subjects of Male Osteoporosis in Mainland China

NCT06332014 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 102

Last updated 2026-02-12

No results posted yet for this study

Summary

The primary objective of this study is to evaluate the efficacy of Prolia on lumbar spine BMD at 12 months.

Conditions

Interventions

DRUG

Prolia

Partcipants will receive subcutaneous (SC) injections of Prolia Q6M.

Sponsors & Collaborators

Principal Investigators

  • MD · Amgen

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
30 Years
Max Age
90 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-08-06
Primary Completion
2027-01-23
Completion
2027-01-23

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06332014 on ClinicalTrials.gov